Abstract / Summary
Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.
Topics
CAR-T cell therapy researchOpen access
Primary Source
Cell and Gene Therapy Insights